^
    Back
    Association details:
    Biomarker:IGH-CRLF2 fusion
    Cancer:Childhood B Acute Lymphoblastic Leukemia
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2012
    Title:

    Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

    Published date:
    10/25/2012
    Excerpt:
    We, therefore, investigated the efficacy of the JAK inhibitor ruxolitinib and the mTOR inhibitor rapamycin in xenograft models of 8 pediatric B-ALL cases with and without CRLF2 and JAK genomic lesions….ruxolitinib yielded only a partial response (lower splenic blast count with no difference in peripheral blast count) in xenograft VI, which does not harbor a JAK mutation but is CRLF2-rearranged...
    DOI:
    10.1182/blood-2012-03-415448